Objective To explore cost-effectiveness of targeted therapies (TTs) in the treatment of
metastatic renal cell carcinoma (mRCC) in a real-world context using a nationwide …

Objectives: The objective of this study was to describe treatment patterns, survival,
healthcare use and costs in patients with metastatic renal cell carcinoma (mRCC) in a real …

Background Limited data exist on the economic consequences of implementing targeted
therapy (TT) for metastatic renal cell carcinoma (RCC) in a real-world setting. Objective To …

ABSTRACT Background: Metastatic RCC (mRCC) treatment has been revolutionized with
11 approved targeted agents. We report patterns of practice, outcomes and …

Abstract Information on detailed treatment costs and the economic burden of renal cell
carcinoma (RCC) is rare. The current study provides treatment costs and outcomes of …

Background Targeted biologic therapy has been proven to be effective compared to the
current therapy of metastatic renal cell carcinoma (mRCC) in clinical studies as well as in …

Methods Clinicopathological and administrative data of patients with mRCC from our
institution were retrospectively collected from January 2000 to August 2014. Patients were …

Background Patient characteristics and survival outcomes in randomized trials may be
different from those in real-life clinical practice. The objective of this study was to describe …

Aim To evaluate the implementation of targeted therapy on overall survival (OS) in a
complete national cohort of patients with metastatic renal cell carcinoma (mRCC). Methods …

Study Type–Therapy (economic) Level of Evidence 2b What's known on the subject? and
What does the study add? Cost‐effectiveness of new targeted molecular therapies in …